62c/share NPV-$2b Potential Sales-US Army backing-Possible Anti-depression and Parkinsons drug - Global Top 5 Clinical Trials - US Fund buying in - GIDDY UP NEU!!!
From my observations as a shareholder I think NEU seems massively undervalued. With the US Army being behind NEU?s NNZ-2566 and aware of NEU's other potential drugs this could easily be much much higher than it is now. This sleepy NZ based unknown may be about to awaken.
I note five positives:
1- The NNZ-2566 Clinical Trial on women seems to have been completed. Results soon? See: http://www.clinicaltrials.gov/ct2/show/NCT00961779?term=neuren&rank=1
2- An influential report at: http://thomsonreuters.com/content/scientific/pdf/ls/pharma_matters/the_ones_to_watch.pdf places NNZ-2566 as one of the top five most promising drugs entering Phase 2 trials, mentioning managements forecast potential sales market in the US alone of US$2b;
3- Neuren seems to have released an internal forecast potential NPV calculation of US$250 million (or approx, 62c per NEU share undiluted) http://www.neurenpharma.com/ssl/cms/files_cms/NNZ-2566%20Overview%20July%202009.pdf
4- NEU's other major drug candidate Motiva appears to show promise in the massive market for anti-depression drugs as well as Parkinson's disease. "A previous Phase II study of Motiva? in post-stroke patients with depression showed a statistically significant benefit for patients with apathy. Apathy is a potentially debilitating syndrome that occurs frequently among patients who have had a stroke as well as patients with depression, Parkinson?s disease, traumatic brain injury, schizophrenia and many other neurological and psychiatric conditions." http://www.neurenpharma.com/ssl/cms/files_cms/NEU%20UWA%20Motiva%20trial.pdf . The US military is very concerned about the effects of depression in its ranks too. See: http://www.army.mil/-news/2010/09/14/45152-focusing-on-the-silent-killer/index.html?ref=home-ata72-img and http://www.army.mil/-news/2010/09/30/45898-army-observes-national-depression-awareness-month/?ref=news-health-title3
5- US Based fund Spring Tree continue to quietly build their stake in Neuren. Their peers may notice and this may attract some other big US fund buyers.
With a current share price of 1.9c and a market value of approx. A$8 million, with A$3m in cash and a fully funded clinical trial any re-rating could be quite significant. Surely at some point over the next year or so, especially if NNZ-2566 proves successfull, this could be a big performer. Why wouldn't you buy it? Why would you sell it? http://www.youtube.com/watch?v=XxqcmfYb0OI
Note: Please do your own research.I am a buyer now but will be a seller if they move higher.
